A seven-year international, multi-center clinical trial led by London Health Sciences Centre Research Institute (LHSCRI) and ...

A seven-year international, multi-centre clinical trial led by London Health Sciences Centre Research Institute (LHSCRI) and ...

New deployment model provides fully-managed database performance directly within a customer’s Google Cloud account ...

Durham-based TruTechnologies has secured a strategic growth investment from LLR Partners to accelerate the expansion of its real-time clinical trial oversight solutions and fuel the next phase of ...

An expert discusses how long-term safety considerations are evaluated through clinical trial data and postmarketing ...

SINGLE clinical trial endpoints often fall short in capturing the full scope of patient experience, particularly in complex ...

Google parent company Alphabet’s strong Q2 2025 results were driven by double-digit growth in Google Cloud Platform (GCP), AI ...

The new pill, called AD109, is a combination of atomoxetine and aroxybutynin, two drugs that tell your brain to keep the ...

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

- Enrollment initiated in dose expansion cohorts in Phase 1 clinical trial of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with KRASG12D-mutant pancreatic, colorectal, and ...

Real-world data confirm Mvasi's safety as a cost-effective alternative to reference bevacizumab (Avastin) for treating retinal conditions.